Russ Trenary President & CEO Caution: Investigational device in the U.S.  Limited by Federal Law to Investigational Use.

InnFocus Update 1) Define the winning formula 2) Clinical results 3) Status of our US IDE

Our Goal Provide a safe, effective, easy to perform, cost effective, alternative for surgical treatment of Glaucoma. Primary Open Angle Glaucoma is our first area of investigation.

Requirements for success A proven drainage path that provides for IOP ≤ 14 mmHg A very inert biomaterial to minimize foreign body reaction A shunt design that will remain patent, prevent chronic hypotony, leakage, or migration An antiproliferative drug to minimize the initial surgical insult

The Winning Key is the SIBS Material There is one stretchy biomaterial that will not provoke scar tissue in the eye Poly(styrene-block-isobutylene-block-styrene) “SIBS” SIBS is ultra-stable and will not degrade in the body No degradation means no chronic inflammation and minimal scar SIBS is used on drug eluting coronary stents (TAXUS) Twelve-year history of use in the body Licensed from BSC for use in the eye

Excellent material but what about shunt design? Make the device thin and soft to conform to the curvature of the eye. Make the lumen sufficiently large to allow cells to pass yet small and long enough to prevent hypotony. Add a fin to prevent migration and leakage around the outside of the tube.

Implanting the InnFocus MicroShunt™ 2.8

Implanting the InnFocus MicroShunt™ 2.8

Implanting the InnFocus MicroShunt™ 2.8

Implanting the InnFocus MicroShunt™ 2.7

Clinical study Baseline Characteristics: Dominican Republic and France 35 POAG eyes All failed maximum tolerated medication Implanted 23 MicroShunts™ only, and 12 combined with cataract surgery Baseline IOP = 23.8 ± 5.3 mmHg Baseline meds per patient = 2.8 ± 1.2

Change in IOP with time for the InnFocus MicroShunt™ Combined data for Dominican Republic and France Baseline IOP = 23.8 ± 5.3 mmHg Average long-term IOP = 11.3 ± 3.2 mmHg AGIS zone for no progression of vision loss Courtesy Dr. Juan Batlle and Dr. Isabelle Riss

Conclusions from Studies in Dominican Republic and France; Data out to 2 Years IOP reduction of 55% from baseline to 11.3 ± 3.2 mmHg 82% of eyes with IOP ≤ 14 mmHg 89% reduction in glaucoma meds to 0.3 med/patient 89% of patients entirely off glaucoma meds Transient hypotony < 5 mmHg after Day 1 = 12% all resolved spontaneously No long-term sight-threatening adverse events No cases of endophthalmitis, chronic hypotony, choroidal hemorrhage Easy to perform and quick alternative to tube or trabeculectomy procedures

Meeting requirements for success in OUS studies? √ A proven drainage path that provides for IOP ≤ 14 mmHg √ A very inert biomaterial to minimize foreign body reaction √ A shunt design that will remain patent, prevent chronic hypotony, leakage, or migration √ An antiproliferative drug to minimize the initial surgical insult

US IDE Study Design Prospective, randomized, controlled, masked, multicenter study Phakic and pseudophakic stratified Two study groups test group is InnFocus MicroShunt™ with MMC control group is trabeculectomy with MMC Two phases with two year follow-up

The Business: Intellectual Property, Regulatory, Financing Issued US Patents 5,741,331 – SIBS for implant applications 7,431,709 – SIBS for use as a drainage tube 7,594,899 – Any tube from AC, w/wo MMC 7,837,644 – SIBS as drainage tube, w/wo MMC Others pending Regulatory CE Mark received January 2012 FDA clearance and initiation of phase I implants Q3, 2013 Financing $10 million from Boston Scientific Corporation, plus $22 million from Hoya, Saints Capital Everest and Angels 2.4

Board of Directors and Management Jean-Luc Boulnois, Ph.D. Scott Halsted Randy Lindholm Leonard Pinchuk, Ph.D. John Sheets, Ph.D. Russ Trenary Russ Trenary President & CEO Leonard Pinchuk, Ph.D. Founder, CSO Bruce A. Weber, MBA V.P., Reg., Clinical. and QA Yasushi P. Kato, Ph.D. V.P. R&D John B. Martin Jr. Chief Engineer, Co-founder

Thank you